Reaction
Short-Bowel Syndrome reporting signals
As of the last recalculation, Short-Bowel Syndrome appears in 643 FAERS reports alongside 9 co-occurring drug terms. The strongest observed disproportionality signal is TEDUGLUTIDE (PRR 158.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Teduglutide | 60 | 158.9 | 159.6 |
| Diphenoxylate Hydrochloride And Atropine Sulfate | 23 | 56.3 | 56.4 |
| Cholestyramine | 17 | 46.7 | 46.8 |
| Octreotide Acetate | 30 | 33.2 | 33.2 |
| Vedolizumab | 54 | 22.1 | 22.1 |
| Rifaximin | 10 | 15.7 | 15.7 |
| Panitumumab | 7 | 14.6 | 14.6 |
| Tapentadol Hydrochloride | 12 | 11.8 | 11.8 |
| Risankizumab-Rzaa | 27 | 11.1 | 11.1 |